Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy

 
• By Mandy Jackson

Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).

business arrow target direction concept to success. Finance growth vector
Health care is one of Asahi Kasei's three main growth pillars • Source: Shutterstock

More from Deals

More from Business